U.S. Tech Hardware Stock News

NYSE:JOBY
NYSE:JOBYAirlines

ITC Probe Clouds Delta Joby Partnership And Raises NYSE JOBY Risk Profile

Delta Air Lines has warned that an ongoing US International Trade Commission probe could disrupt its partnership with Joby Aviation (NYSE:JOBY). The investigation is tied to patent infringement allegations brought by competitor Archer Aviation. Delta indicated that an adverse outcome could potentially restrict or remove Joby eVTOL aircraft from the US market. Joby Aviation, which is developing electric vertical take off and landing aircraft for short distance passenger flights, has been a...
NYSE:HE
NYSE:HEElectric Utilities

A Look At Hawaiian Electric (HE) Valuation After Maui Settlement Credit Upgrade And Q1 Earnings

Hawaiian Electric Industries (HE) is back in focus after finalizing the global Maui wildfire settlement and making the first of four annual payments, alongside first quarter earnings and a credit rating upgrade from Moody's. See our latest analysis for Hawaiian Electric Industries. There has been a sharp reset in sentiment, with the share price down 11.2% over the past 90 days but still up 17.4% year to date. The 1 year total shareholder return of 38.7% contrasts with a much weaker 3 and 5...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Assessing Syndax Pharmaceuticals (SNDX) Valuation After Stronger Revenue And Narrower Losses

Why the latest earnings matter for Syndax Pharmaceuticals (SNDX) Syndax Pharmaceuticals (SNDX) reported first quarter 2026 revenue of US$64.86 million compared with US$20.04 million a year earlier, with net loss narrowing to US$42.67 million and loss per share at US$0.48, down from US$0.98. See our latest analysis for Syndax Pharmaceuticals. Alongside the stronger quarterly figures, Syndax Pharmaceuticals’ recent price action has been mixed, with a 7 day share price return of 7.67% and a 30...
NasdaqCM:ASTH
NasdaqCM:ASTHHealthcare

A Look At Astrana Health (ASTH) Valuation After A Sharp Multi‑Period Share Price Rally

Astrana Health stock performance snapshot Astrana Health (ASTH) has drawn investor attention after a strong recent run, with the stock up 8.9% in the past day, 12.3% over the week, and 42.2% over the past month. See our latest analysis for Astrana Health. Those short term share price moves sit on top of a much stronger run, with a 90 day share price return of 103.9% and a 1 year total shareholder return of 37.7%. This points to building momentum as investors reassess Astrana Health's growth...
NYSE:BR
NYSE:BRProfessional Services

Broadridge Extends LTX Reach As Major Banks Deepen Bond Trading Ties

Broadridge Financial Solutions (NYSE:BR) added Goldman Sachs, J.P. Morgan, TD Securities, Morgan Stanley, and Bank of America as fully integrated liquidity providers on its LTX bond trading platform. J.P. Morgan and TD Securities joined the LTX board as part of the expansion, deepening their involvement with the AI powered electronic bond trading venue. The new relationships increase the institutional presence on LTX and broaden its reach across the corporate bond market. For you as an...
NYSE:IBP
NYSE:IBPConsumer Durables

Does Installed Building Products (IBP) Dividend Hike Reveal a Deeper Shift in Its Earnings Mix?

Installed Building Products, Inc. reported first-quarter 2026 results with sales of US$660.5 million and net income of US$34.8 million, while also appointing Ryan Ricketts as Director of Investor Relations and Financial Planning and declaring a US$0.39 per-share quarterly dividend payable on June 30, 2026. The quarter highlighted pressure on residential installation volumes alongside growth in commercial and manufacturing segments and a higher dividend, underscoring a shift in the company’s...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Palantir Technologies (PLTR) Is Down 5.6% After Strong Q1 Beat And Raised 2026 Outlook

In the first quarter of 2026, Palantir Technologies reported revenue of US$1,632.58 million and net income of US$870.53 million, sharply higher than a year earlier, and raised its 2026 revenue outlook to between US$7.65 billion and US$7.66 billion while guiding to continued GAAP profitability. A new three-year partnership with Cleveland-Cliffs to embed Palantir’s AI platform directly into core manufacturing and commercial workflows underscores how operational AI deployments are increasingly...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

If you are wondering whether Amylyx Pharmaceuticals at US$14.73 is still offering value after a strong run, it helps to step back and look at what the price is really reflecting. The stock is up 29.0% year to date and 220.2% over the past year, even though it has fallen about 10.5% over the past week and 10.0% over the past month. These moves can change how you think about both opportunity and risk. Across financial media and industry commentary, recent attention has focused on Amylyx as a...
NYSE:BLK
NYSE:BLKCapital Markets

Assessing BlackRock (NYSE:BLK) Valuation As Private Credit And Technology Efforts Gain Traction

BlackRock (BLK) has been in focus after rolling out new private credit tools on its Aladdin platform with Preqin and expanding private credit data access. These moves are tied closely to its technology and subscription revenue ambitions. See our latest analysis for BlackRock. Recent private credit launches on Aladdin and expanded data access via Preqin have coincided with a 1-month share price return of 8.56% and a 1-year total shareholder return of 15.57%. The 3-year total shareholder return...
NasdaqGS:INNV
NasdaqGS:INNVHealthcare

Why InnovAge (INNV) Is Down 7.3% After Raising 2026 Revenue Guidance Amid Wider Legal Losses

In May 2026, InnovAge Holding Corp. reported third-quarter results showing revenue rising to US$251.94 million from US$218.14 million a year earlier, but a wider net loss of US$29.46 million driven largely by higher legal and litigation expenses including settlements and accruals. The company also raised its fiscal 2026 revenue guidance to US$950 million–US$975 million, highlighting operational momentum in its PACE model even as profitability remains pressured by legal costs and ongoing...
NYSE:MFA
NYSE:MFAMortgage REITs

Will MFA’s Q1 Net Loss and Buybacks Reshape MFA Financial's (MFA) Capital Allocation Narrative?

MFA Financial, Inc. reported first-quarter 2026 results showing a net loss of US$984,000 and basic and diluted loss per share of US$0.11 from continuing operations, while also completing a buyback of 500,660 shares for US$5.01 million under its February 18, 2026 repurchase authorization. Management linked the loss to higher rates, wider mortgage spreads, and geopolitical tensions, while simultaneously pursuing expense reduction, portfolio growth and loan resolutions, underscoring a tension...
NasdaqGM:ARRY
NasdaqGM:ARRYElectrical

Array Technologies (ARRY) Valuation Check After Strong Q1 Revenue, Record Order Book And New Product Launch

Array Technologies (ARRY) drew fresh attention after Q1 2026 revenue came in ahead of expectations, supported by a record US$2.4b order book and reaffirmed guidance, even as the company reported a GAAP net loss. See our latest analysis for Array Technologies. The share price has reacted quickly to the Q1 update, with a 1-day share price return of 4.51% and a 7-day return of 11.88%, adding to a 30-day gain of 19.69%. However, this sits against a 3-year total shareholder return that is down...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Jazz Pharmaceuticals (JAZZ) Is Up 8.5% After Q1 Profit Rebound And Ziihera Priority Review – Has The Bull Case Changed?

In the first quarter of 2026, Jazz Pharmaceuticals reported revenue of US$1,068.9 million, up from US$897.8 million a year earlier, and turned a US$92.5 million net loss into US$293.1 million in net income, with earnings per share swinging from a loss to US$4.43 on a diluted basis. At the same time, the FDA accepted a Priority Review for Jazz’s Ziihera (zanidatamab-hrii) in first-line HER2-positive advanced gastric and related cancers, underscoring the company’s push to expand its oncology...
NasdaqGS:NBTB
NasdaqGS:NBTBBanks

A Look At NBT Bancorp (NBTB) Valuation After Strong Q1 2026 Earnings And Credit Quality Update

NBT Bancorp (NBTB) stock is in focus after the company reported Q1 2026 net income of US$51.1 million, up from US$36.7 million a year earlier, alongside lower loan loss provisions. See our latest analysis for NBT Bancorp. The stock has gathered modest positive momentum, with a 7 day share price return of 3.45% and a year to date share price return of 9.62%, while the 3 year total shareholder return of 51.51% points to a stronger longer term record. If this banking update has you thinking...
NYSE:LPG
NYSE:LPGOil and Gas

Dorian LPG’s One-Off US$1 Dividend Could Be A Game Changer For DorianG (LPG)

Earlier this month, Dorian LPG Ltd. declared an irregular cash dividend of US$1.00 per share, totaling about US$42.80 million, payable on or about May 28, 2026 to shareholders of record as of May 18, 2026. This one-off dividend signals a meaningful return of excess capital to investors and offers fresh insight into how management currently prioritizes cash allocation. We’ll now examine how this irregular US$1.00 per-share dividend shapes Dorian LPG’s existing investment narrative and capital...
NasdaqCM:PGY
NasdaqCM:PGYSoftware

Why Pagaya Technologies (PGY) Is Up 5.8% After Raising 2026 Outlook And Announcing CFO Transition

Pagaya Technologies reported first-quarter 2026 results with revenue of US$317.94 million and net income of US$24.69 million, raised its full-year 2026 guidance, and announced that Chief Strategy Officer Jonathan Dobres will become Chief Financial Officer on June 15, 2026, while current CFO Evangelos Perros stays on as Strategic Executive Advisor through year-end. The company also signed a new partnership in early May 2026 for Sezzle to embed Pagaya’s AI underwriting platform at checkout,...